Agilent Technologies, Inc. (NYSE: A) Stock Competitors & Peer Comparison
See A's competitors and their performance on the NYSE and across the wider stock market.
Peer Comparison Table: Medical - Diagnostics & Research Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for A and its NYSE peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| A | $174.76 | +1.73% | 49.3B | 30.08 | $5.81 | +0.59% |
| DHR-PB | $1,261.26 | -0.78% | 916.8B | 146.01 | $8.64 | +0.66% |
| TMO | $694.76 | +2.63% | 257.5B | 30.00 | $23.16 | +0.27% |
| DHR | $230.25 | +1.73% | 161.9B | 28.86 | $7.98 | +0.66% |
| IDXX | $676.04 | +0.79% | 53.3B | 47.54 | $14.22 | N/A |
| WAT | $457.60 | +1.00% | 44.9B | 33.45 | $13.68 | N/A |
| IQV | $271.83 | +2.62% | 44.8B | 22.40 | $12.13 | N/A |
| NTRA | $310.67 | -14.59% | 44.7B | -235.14 | -$1.32 | N/A |
| MTD | $1,722.15 | +2.57% | 34.5B | 39.56 | $43.51 | N/A |
| ILMN | $213.13 | +2.47% | 32.2B | 42.36 | $5.03 | N/A |
Stock Comparison
Danaher Corporation (NYSE: DHR-PB)
A vs DHR-PB Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, DHR-PB has a market cap of 916.8B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while DHR-PB trades at $1,261.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas DHR-PB's P/E ratio is 146.01. In terms of profitability, A's ROE is +0.20%, compared to DHR-PB's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to DHR-PB. This indicates higher risk in terms of short-term price fluctuations for A.Check DHR-PB's competition here
Thermo Fisher Scientific Inc. (NYSE: TMO)
A vs TMO Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, TMO has a market cap of 257.5B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while TMO trades at $694.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas TMO's P/E ratio is 30.00. In terms of profitability, A's ROE is +0.20%, compared to TMO's ROE of +0.13%. Regarding short-term risk, A is less volatile compared to TMO. This indicates lower risk in terms of short-term price fluctuations for A.Check TMO's competition here
Danaher Corporation (NYSE: DHR)
A vs DHR Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, DHR has a market cap of 161.9B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while DHR trades at $230.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas DHR's P/E ratio is 28.86. In terms of profitability, A's ROE is +0.20%, compared to DHR's ROE of +0.08%. Regarding short-term risk, A is less volatile compared to DHR. This indicates lower risk in terms of short-term price fluctuations for A.Check DHR's competition here
IDEXX Laboratories, Inc. (NASDAQ: IDXX)
A vs IDXX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, IDXX has a market cap of 53.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while IDXX trades at $676.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas IDXX's P/E ratio is 47.54. In terms of profitability, A's ROE is +0.20%, compared to IDXX's ROE of +0.71%. Regarding short-term risk, A is less volatile compared to IDXX. This indicates lower risk in terms of short-term price fluctuations for A.Check IDXX's competition here
Waters Corporation (NYSE: WAT)
A vs WAT Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, WAT has a market cap of 44.9B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while WAT trades at $457.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas WAT's P/E ratio is 33.45. In terms of profitability, A's ROE is +0.20%, compared to WAT's ROE of +0.01%. Regarding short-term risk, A is more volatile compared to WAT. This indicates higher risk in terms of short-term price fluctuations for A.Check WAT's competition here
IQVIA Holdings Inc. (NYSE: IQV)
A vs IQV Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, IQV has a market cap of 44.8B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while IQV trades at $271.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas IQV's P/E ratio is 22.40. In terms of profitability, A's ROE is +0.20%, compared to IQV's ROE of +0.22%. Regarding short-term risk, A is less volatile compared to IQV. This indicates lower risk in terms of short-term price fluctuations for A.Check IQV's competition here
Natera, Inc. (NASDAQ: NTRA)
A vs NTRA Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NTRA has a market cap of 44.7B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NTRA trades at $310.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NTRA's P/E ratio is -235.14. In terms of profitability, A's ROE is +0.20%, compared to NTRA's ROE of -0.09%. Regarding short-term risk, A is less volatile compared to NTRA. This indicates lower risk in terms of short-term price fluctuations for A.Check NTRA's competition here
Mettler-Toledo International Inc. (NYSE: MTD)
A vs MTD Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MTD has a market cap of 34.5B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MTD trades at $1,722.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MTD's P/E ratio is 39.56. In terms of profitability, A's ROE is +0.20%, compared to MTD's ROE of +149.66%. Regarding short-term risk, A is less volatile compared to MTD. This indicates lower risk in terms of short-term price fluctuations for A.Check MTD's competition here
Illumina, Inc. (NASDAQ: ILMN)
A vs ILMN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ILMN has a market cap of 32.2B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ILMN trades at $213.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ILMN's P/E ratio is 42.36. In terms of profitability, A's ROE is +0.20%, compared to ILMN's ROE of +0.31%. Regarding short-term risk, A is less volatile compared to ILMN. This indicates lower risk in terms of short-term price fluctuations for A.Check ILMN's competition here
Labcorp Holdings Inc. (NYSE: LH)
A vs LH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, LH has a market cap of 29.8B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while LH trades at $366.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas LH's P/E ratio is 21.76. In terms of profitability, A's ROE is +0.20%, compared to LH's ROE of +0.12%. Regarding short-term risk, A is less volatile compared to LH. This indicates lower risk in terms of short-term price fluctuations for A.Check LH's competition here
Quest Diagnostics Incorporated (NYSE: DGX)
A vs DGX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, DGX has a market cap of 28.2B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while DGX trades at $255.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas DGX's P/E ratio is 25.22. In terms of profitability, A's ROE is +0.20%, compared to DGX's ROE of +0.15%. Regarding short-term risk, A is less volatile compared to DGX. This indicates lower risk in terms of short-term price fluctuations for A.Check DGX's competition here
Guardant Health, Inc. (NASDAQ: GH)
A vs GH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, GH has a market cap of 20.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while GH trades at $150.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas GH's P/E ratio is -43.33. In terms of profitability, A's ROE is +0.20%, compared to GH's ROE of +2.49%. Regarding short-term risk, A is less volatile compared to GH. This indicates lower risk in terms of short-term price fluctuations for A.Check GH's competition here
Exact Sciences Corporation (NASDAQ: EXAS)
A vs EXAS Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, EXAS has a market cap of 20B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while EXAS trades at $104.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas EXAS's P/E ratio is -95.37. In terms of profitability, A's ROE is +0.20%, compared to EXAS's ROE of -0.04%. Regarding short-term risk, A is more volatile compared to EXAS. This indicates higher risk in terms of short-term price fluctuations for A.Check EXAS's competition here
Medpace Holdings, Inc. (NASDAQ: MEDP)
A vs MEDP Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MEDP has a market cap of 18.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MEDP trades at $653.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MEDP's P/E ratio is 36.22. In terms of profitability, A's ROE is +0.20%, compared to MEDP's ROE of +1.00%. Regarding short-term risk, A is less volatile compared to MEDP. This indicates lower risk in terms of short-term price fluctuations for A.Check MEDP's competition here
Revvity, Inc. (NYSE: RVTY)
A vs RVTY Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, RVTY has a market cap of 17.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while RVTY trades at $155.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas RVTY's P/E ratio is 29.01. In terms of profitability, A's ROE is +0.20%, compared to RVTY's ROE of +0.04%. Regarding short-term risk, A is less volatile compared to RVTY. This indicates lower risk in terms of short-term price fluctuations for A.Check RVTY's competition here
Illumina, Inc. Common Stock Ex-distribution When-Issued (NASDAQ: ILMNV)
A vs ILMNV Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ILMNV has a market cap of 17B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ILMNV trades at $107.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ILMNV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to ILMNV's ROE of N/A. Regarding short-term risk, A is more volatile compared to ILMNV. This indicates higher risk in terms of short-term price fluctuations for A.Check ILMNV's competition here
Charles River Laboratories International, Inc. (NYSE: CRL)
A vs CRL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CRL has a market cap of 16.2B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CRL trades at $337.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CRL's P/E ratio is 34.09. In terms of profitability, A's ROE is +0.20%, compared to CRL's ROE of +0.01%. Regarding short-term risk, A is less volatile compared to CRL. This indicates lower risk in terms of short-term price fluctuations for A.Check CRL's competition here
ICON Public Limited Company (NASDAQ: ICLR)
A vs ICLR Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ICLR has a market cap of 15.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ICLR trades at $204.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ICLR's P/E ratio is 16.71. In terms of profitability, A's ROE is +0.20%, compared to ICLR's ROE of +0.05%. Regarding short-term risk, A is less volatile compared to ICLR. This indicates lower risk in terms of short-term price fluctuations for A.Check ICLR's competition here
PerkinElmer, Inc. (NYSE: PKI)
A vs PKI Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, PKI has a market cap of 14.5B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while PKI trades at $115.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas PKI's P/E ratio is 41.45. In terms of profitability, A's ROE is +0.20%, compared to PKI's ROE of +0.04%. Regarding short-term risk, A is more volatile compared to PKI. This indicates higher risk in terms of short-term price fluctuations for A.Check PKI's competition here
Qiagen N.V. (NYSE: QGEN)
A vs QGEN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, QGEN has a market cap of 10.4B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while QGEN trades at $50.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas QGEN's P/E ratio is 20.79. In terms of profitability, A's ROE is +0.20%, compared to QGEN's ROE of +0.12%. Regarding short-term risk, A is more volatile compared to QGEN. This indicates higher risk in terms of short-term price fluctuations for A.Check QGEN's competition here
RadNet, Inc. (NASDAQ: RDNT)
A vs RDNT Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, RDNT has a market cap of 6B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while RDNT trades at $76.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas RDNT's P/E ratio is 164.87. In terms of profitability, A's ROE is +0.20%, compared to RDNT's ROE of -0.02%. Regarding short-term risk, A is less volatile compared to RDNT. This indicates lower risk in terms of short-term price fluctuations for A.Check RDNT's competition here
GRAIL Inc. (NASDAQ: GRAL)
A vs GRAL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, GRAL has a market cap of 5.4B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while GRAL trades at $121.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas GRAL's P/E ratio is -12.45. In terms of profitability, A's ROE is +0.20%, compared to GRAL's ROE of -0.16%. Regarding short-term risk, A is less volatile compared to GRAL. This indicates lower risk in terms of short-term price fluctuations for A.Check GRAL's competition here
BillionToOne, Inc. (NASDAQ: BLLN)
A vs BLLN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BLLN has a market cap of 5.4B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BLLN trades at $113.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BLLN's P/E ratio is 162.81. In terms of profitability, A's ROE is +0.20%, compared to BLLN's ROE of +0.09%. Regarding short-term risk, A is less volatile compared to BLLN. This indicates lower risk in terms of short-term price fluctuations for A.Check BLLN's competition here
Sotera Health Company (NASDAQ: SHC)
A vs SHC Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, SHC has a market cap of 4.6B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while SHC trades at $16.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas SHC's P/E ratio is 16.68. In terms of profitability, A's ROE is +0.20%, compared to SHC's ROE of +0.26%. Regarding short-term risk, A is more volatile compared to SHC. This indicates higher risk in terms of short-term price fluctuations for A.Check SHC's competition here
Syneos Health, Inc. (NASDAQ: SYNH)
A vs SYNH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, SYNH has a market cap of 4.5B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while SYNH trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas SYNH's P/E ratio is 61.40. In terms of profitability, A's ROE is +0.20%, compared to SYNH's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to SYNH. This indicates higher risk in terms of short-term price fluctuations for A.Check SYNH's competition here
CareDx, Inc (NASDAQ: CDNA)
A vs CDNA Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CDNA has a market cap of 4.1B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CDNA trades at $78.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CDNA's P/E ratio is 93.46. In terms of profitability, A's ROE is +0.20%, compared to CDNA's ROE of +0.34%. Regarding short-term risk, A is less volatile compared to CDNA. This indicates lower risk in terms of short-term price fluctuations for A.Check CDNA's competition here
Olink Holding AB (publ) (NASDAQ: OLK)
A vs OLK Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, OLK has a market cap of 3.2B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while OLK trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas OLK's P/E ratio is -96.59. In terms of profitability, A's ROE is +0.20%, compared to OLK's ROE of -0.07%. Regarding short-term risk, A is more volatile compared to OLK. This indicates higher risk in terms of short-term price fluctuations for A.Check OLK's competition here
NeoGenomics, Inc. (NASDAQ: NEO)
A vs NEO Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NEO has a market cap of 2.2B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NEO trades at $16.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NEO's P/E ratio is 129.54. In terms of profitability, A's ROE is +0.20%, compared to NEO's ROE of -0.04%. Regarding short-term risk, A is less volatile compared to NEO. This indicates lower risk in terms of short-term price fluctuations for A.Check NEO's competition here
Veracyte, Inc. (NASDAQ: VCYT)
A vs VCYT Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, VCYT has a market cap of 1.9B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while VCYT trades at $24.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas VCYT's P/E ratio is 12.07. In terms of profitability, A's ROE is +0.20%, compared to VCYT's ROE of +0.09%. Regarding short-term risk, A is less volatile compared to VCYT. This indicates lower risk in terms of short-term price fluctuations for A.Check VCYT's competition here
GeneDx Holdings Corp. (NASDAQ: WGS)
A vs WGS Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, WGS has a market cap of 1.9B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while WGS trades at $62.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas WGS's P/E ratio is 173.25. In terms of profitability, A's ROE is +0.20%, compared to WGS's ROE of -0.39%. Regarding short-term risk, A is less volatile compared to WGS. This indicates lower risk in terms of short-term price fluctuations for A.Check WGS's competition here
Personalis, Inc. (NASDAQ: PSNL)
A vs PSNL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, PSNL has a market cap of 1.7B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while PSNL trades at $15.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas PSNL's P/E ratio is -14.48. In terms of profitability, A's ROE is +0.20%, compared to PSNL's ROE of -0.50%. Regarding short-term risk, A is more volatile compared to PSNL. This indicates higher risk in terms of short-term price fluctuations for A.Check PSNL's competition here
OPKO Health, Inc. (NASDAQ: OPK)
A vs OPK Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, OPK has a market cap of 1.3B. Regarding current trading prices, A is priced at $174.76 on the NYSE, while OPK trades at $1.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas OPK's P/E ratio is -19.17. In terms of profitability, A's ROE is +0.20%, compared to OPK's ROE of -0.12%. Regarding short-term risk, A is less volatile compared to OPK. This indicates lower risk in terms of short-term price fluctuations for A.Check OPK's competition here
Castle Biosciences, Inc. (NASDAQ: CSTL)
A vs CSTL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CSTL has a market cap of 993.2M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CSTL trades at $32.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CSTL's P/E ratio is -49.26. In terms of profitability, A's ROE is +0.20%, compared to CSTL's ROE of -0.05%. Regarding short-term risk, A is less volatile compared to CSTL. This indicates lower risk in terms of short-term price fluctuations for A.Check CSTL's competition here
Fulgent Genetics, Inc. (NASDAQ: FLGT)
A vs FLGT Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, FLGT has a market cap of 654.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while FLGT trades at $23.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas FLGT's P/E ratio is 2378.00. In terms of profitability, A's ROE is +0.20%, compared to FLGT's ROE of -0.09%. Regarding short-term risk, A is less volatile compared to FLGT. This indicates lower risk in terms of short-term price fluctuations for A.Check FLGT's competition here
GRAIL, Inc. Common Stock (NASDAQ: GRALV)
A vs GRALV Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, GRALV has a market cap of 579.4M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while GRALV trades at $18.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas GRALV's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to GRALV's ROE of N/A. Regarding short-term risk, A is less volatile compared to GRALV. This indicates lower risk in terms of short-term price fluctuations for A.Check GRALV's competition here
Myriad Genetics, Inc. (NASDAQ: MYGN)
A vs MYGN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MYGN has a market cap of 564.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MYGN trades at $5.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MYGN's P/E ratio is -45.38. In terms of profitability, A's ROE is +0.20%, compared to MYGN's ROE of -0.40%. Regarding short-term risk, A is less volatile compared to MYGN. This indicates lower risk in terms of short-term price fluctuations for A.Check MYGN's competition here
Global Cord Blood Corporation (NYSE: CO)
A vs CO Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CO has a market cap of 400.1M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CO trades at $2.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CO's P/E ratio is 5.06. In terms of profitability, A's ROE is +0.20%, compared to CO's ROE of +0.11%. Regarding short-term risk, A is less volatile compared to CO. This indicates lower risk in terms of short-term price fluctuations for A.Check CO's competition here
Standard BioTools Inc. (NASDAQ: FLDM)
A vs FLDM Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, FLDM has a market cap of 294.2M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while FLDM trades at $3.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas FLDM's P/E ratio is -4.74. In terms of profitability, A's ROE is +0.20%, compared to FLDM's ROE of +0.26%. Regarding short-term risk, A is less volatile compared to FLDM. This indicates lower risk in terms of short-term price fluctuations for A.Check FLDM's competition here
Exagen Inc. (NASDAQ: XGN)
A vs XGN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, XGN has a market cap of 140.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while XGN trades at $5.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas XGN's P/E ratio is -7.16. In terms of profitability, A's ROE is +0.20%, compared to XGN's ROE of -1.22%. Regarding short-term risk, A is less volatile compared to XGN. This indicates lower risk in terms of short-term price fluctuations for A.Check XGN's competition here
Genetron Holdings Limited (NASDAQ: GTH)
A vs GTH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, GTH has a market cap of 127.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while GTH trades at $4.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas GTH's P/E ratio is -1.11. In terms of profitability, A's ROE is +0.20%, compared to GTH's ROE of -1.01%. Regarding short-term risk, A is more volatile compared to GTH. This indicates higher risk in terms of short-term price fluctuations for A.Check GTH's competition here
Genetic Technologies Limited (NASDAQ: GENE)
A vs GENE Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, GENE has a market cap of 111.2M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while GENE trades at $0.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas GENE's P/E ratio is -38.25. In terms of profitability, A's ROE is +0.20%, compared to GENE's ROE of -1.85%. Regarding short-term risk, A is more volatile compared to GENE. This indicates higher risk in terms of short-term price fluctuations for A.Check GENE's competition here
Freenome, Inc. (NASDAQ: FRNM)
A vs FRNM Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, FRNM has a market cap of 83M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while FRNM trades at $10.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas FRNM's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to FRNM's ROE of N/A. Regarding short-term risk, A is less volatile compared to FRNM. This indicates lower risk in terms of short-term price fluctuations for A.Check FRNM's competition here
Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)
A vs IMDX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, IMDX has a market cap of 81.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while IMDX trades at $2.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas IMDX's P/E ratio is -1.67. In terms of profitability, A's ROE is +0.20%, compared to IMDX's ROE of +2.72%. Regarding short-term risk, A is less volatile compared to IMDX. This indicates lower risk in terms of short-term price fluctuations for A.Check IMDX's competition here
Biodesix, Inc. (NASDAQ: BDSX)
A vs BDSX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BDSX has a market cap of 69.8M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BDSX trades at $8.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BDSX's P/E ratio is -2.71. In terms of profitability, A's ROE is +0.20%, compared to BDSX's ROE of -4.42%. Regarding short-term risk, A is less volatile compared to BDSX. This indicates lower risk in terms of short-term price fluctuations for A.Check BDSX's competition here
Precipio, Inc. (NASDAQ: PRPO)
A vs PRPO Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, PRPO has a market cap of 33.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while PRPO trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas PRPO's P/E ratio is -28.78. In terms of profitability, A's ROE is +0.20%, compared to PRPO's ROE of -0.08%. Regarding short-term risk, A is less volatile compared to PRPO. This indicates lower risk in terms of short-term price fluctuations for A.Check PRPO's competition here
Akumin Inc. (NASDAQ: AKU)
A vs AKU Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, AKU has a market cap of 26.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while AKU trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas AKU's P/E ratio is -0.13. In terms of profitability, A's ROE is +0.20%, compared to AKU's ROE of -5.32%. Regarding short-term risk, A is less volatile compared to AKU. This indicates lower risk in terms of short-term price fluctuations for A.Check AKU's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAF)
A vs BIAF Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BIAF has a market cap of 17.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BIAF trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BIAF's P/E ratio is -0.32. In terms of profitability, A's ROE is +0.20%, compared to BIAF's ROE of -2.57%. Regarding short-term risk, A is less volatile compared to BIAF. This indicates lower risk in terms of short-term price fluctuations for A.Check BIAF's competition here
Chembio Diagnostics, Inc. (NASDAQ: CEMI)
A vs CEMI Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CEMI has a market cap of 16.7M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CEMI trades at $0.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CEMI's P/E ratio is -0.63. In terms of profitability, A's ROE is +0.20%, compared to CEMI's ROE of -0.89%. Regarding short-term risk, A is more volatile compared to CEMI. This indicates higher risk in terms of short-term price fluctuations for A.Check CEMI's competition here
Enzo Biochem, Inc. (NYSE: ENZ)
A vs ENZ Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ENZ has a market cap of 16.4M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ENZ trades at $0.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ENZ's P/E ratio is -2.24. In terms of profitability, A's ROE is +0.20%, compared to ENZ's ROE of -0.39%. Regarding short-term risk, A is less volatile compared to ENZ. This indicates lower risk in terms of short-term price fluctuations for A.Check ENZ's competition here
Quantum Cyber N.V. (NASDAQ: QUCY)
A vs QUCY Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, QUCY has a market cap of 16.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while QUCY trades at $0.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas QUCY's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to QUCY's ROE of -3.65%. Regarding short-term risk, A is less volatile compared to QUCY. This indicates lower risk in terms of short-term price fluctuations for A.Check QUCY's competition here
Psychemedics Corporation (NASDAQ: PMD)
A vs PMD Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, PMD has a market cap of 15.6M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while PMD trades at $2.67.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas PMD's P/E ratio is -5.24. In terms of profitability, A's ROE is +0.20%, compared to PMD's ROE of -0.32%. Regarding short-term risk, A is more volatile compared to PMD. This indicates higher risk in terms of short-term price fluctuations for A.Check PMD's competition here
23andMe Holding Co. (NASDAQ: ME)
A vs ME Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ME has a market cap of 15.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ME trades at $0.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ME's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to ME's ROE of -3.47%. Regarding short-term risk, A is more volatile compared to ME. This indicates higher risk in terms of short-term price fluctuations for A.Check ME's competition here
MDxHealth S.A. (NASDAQ: MDXH)
A vs MDXH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MDXH has a market cap of 15.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MDXH trades at $0.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MDXH's P/E ratio is -0.22. In terms of profitability, A's ROE is +0.20%, compared to MDXH's ROE of +1.43%. Regarding short-term risk, A is less volatile compared to MDXH. This indicates lower risk in terms of short-term price fluctuations for A.Check MDXH's competition here
Mainz Biomed B.V. (NASDAQ: MYNZ)
A vs MYNZ Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MYNZ has a market cap of 14.7M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MYNZ trades at $3.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MYNZ's P/E ratio is -1.33. In terms of profitability, A's ROE is +0.20%, compared to MYNZ's ROE of -1.80%. Regarding short-term risk, A is less volatile compared to MYNZ. This indicates lower risk in terms of short-term price fluctuations for A.Check MYNZ's competition here
Burning Rock Biotech Limited (NASDAQ: BNR)
A vs BNR Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BNR has a market cap of 14.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BNR trades at $13.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BNR's P/E ratio is -15.79. In terms of profitability, A's ROE is +0.20%, compared to BNR's ROE of -0.13%. Regarding short-term risk, A is less volatile compared to BNR. This indicates lower risk in terms of short-term price fluctuations for A.Check BNR's competition here
Check-Cap Ltd. (NASDAQ: CHEK)
A vs CHEK Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CHEK has a market cap of 10.9M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CHEK trades at $1.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CHEK's P/E ratio is -0.43. In terms of profitability, A's ROE is +0.20%, compared to CHEK's ROE of -2.26%. Regarding short-term risk, A is less volatile compared to CHEK. This indicates lower risk in terms of short-term price fluctuations for A.Check CHEK's competition here
Centogene N.V. (NASDAQ: CNTG)
A vs CNTG Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CNTG has a market cap of 9.4M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CNTG trades at $0.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CNTG's P/E ratio is -0.23. In terms of profitability, A's ROE is +0.20%, compared to CNTG's ROE of +3.98%. Regarding short-term risk, A is more volatile compared to CNTG. This indicates higher risk in terms of short-term price fluctuations for A.Check CNTG's competition here
Applied DNA Sciences, Inc. (NASDAQ: APDN)
A vs APDN Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, APDN has a market cap of 7.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while APDN trades at $5.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas APDN's P/E ratio is -0.10. In terms of profitability, A's ROE is +0.20%, compared to APDN's ROE of -7.23%. Regarding short-term risk, A is less volatile compared to APDN. This indicates lower risk in terms of short-term price fluctuations for A.Check APDN's competition here
ENDRA Life Sciences Inc. (NASDAQ: NDRA)
A vs NDRA Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NDRA has a market cap of 7.1M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NDRA trades at $4.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NDRA's P/E ratio is -0.70. In terms of profitability, A's ROE is +0.20%, compared to NDRA's ROE of -2.25%. Regarding short-term risk, A is less volatile compared to NDRA. This indicates lower risk in terms of short-term price fluctuations for A.Check NDRA's competition here
bioAffinity Technologies, Inc. (NASDAQ: BIAFW)
A vs BIAFW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BIAFW has a market cap of 7M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BIAFW trades at $0.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BIAFW's P/E ratio is 0.75. In terms of profitability, A's ROE is +0.20%, compared to BIAFW's ROE of -2.57%. Regarding short-term risk, A is less volatile compared to BIAFW. This indicates lower risk in terms of short-term price fluctuations for A.Check BIAFW's competition here
Invitae Corporation (NYSE: NVTA)
A vs NVTA Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NVTA has a market cap of 5.4M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NVTA trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NVTA's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to NVTA's ROE of -2.02%. Regarding short-term risk, A is less volatile compared to NVTA. This indicates lower risk in terms of short-term price fluctuations for A.Check NVTA's competition here
LumiraDx Limited (NASDAQ: LMDXW)
A vs LMDXW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, LMDXW has a market cap of 5.1M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while LMDXW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas LMDXW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to LMDXW's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDXW. This indicates lower risk in terms of short-term price fluctuations for A.Check LMDXW's competition here
LumiraDx Limited (NASDAQ: LMDX)
A vs LMDX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, LMDX has a market cap of 5.1M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while LMDX trades at $0.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas LMDX's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.20%, compared to LMDX's ROE of -15.58%. Regarding short-term risk, A is less volatile compared to LMDX. This indicates lower risk in terms of short-term price fluctuations for A.Check LMDX's competition here
Advanced Biomed Inc. Common Stock (NASDAQ: ADVB)
A vs ADVB Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ADVB has a market cap of 3.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ADVB trades at $1.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ADVB's P/E ratio is -18.32. In terms of profitability, A's ROE is +0.20%, compared to ADVB's ROE of +1.22%. Regarding short-term risk, A is less volatile compared to ADVB. This indicates lower risk in terms of short-term price fluctuations for A.Check ADVB's competition here
DermTech, Inc. (NASDAQ: DMTK)
A vs DMTK Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, DMTK has a market cap of 3.3M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while DMTK trades at $0.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas DMTK's P/E ratio is -0.04. In terms of profitability, A's ROE is +0.20%, compared to DMTK's ROE of -1.06%. Regarding short-term risk, A is less volatile compared to DMTK. This indicates lower risk in terms of short-term price fluctuations for A.Check DMTK's competition here
Inotiv, Inc. (NASDAQ: NOTV)
A vs NOTV Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NOTV has a market cap of 2.8M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NOTV trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NOTV's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to NOTV's ROE of -0.75%. Regarding short-term risk, A is less volatile compared to NOTV. This indicates lower risk in terms of short-term price fluctuations for A.Check NOTV's competition here
SeqLL Inc. (NASDAQ: SQL)
A vs SQL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, SQL has a market cap of 2.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while SQL trades at $6.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas SQL's P/E ratio is -0.40. In terms of profitability, A's ROE is +0.20%, compared to SQL's ROE of -30.46%. Regarding short-term risk, A is less volatile compared to SQL. This indicates lower risk in terms of short-term price fluctuations for A.Check SQL's competition here
Aspira Women's Health Inc. (NASDAQ: AWH)
A vs AWH Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, AWH has a market cap of 2.5M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while AWH trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas AWH's P/E ratio is -0.09. In terms of profitability, A's ROE is +0.20%, compared to AWH's ROE of +1.62%. Regarding short-term risk, A is more volatile compared to AWH. This indicates higher risk in terms of short-term price fluctuations for A.Check AWH's competition here
iSpecimen Inc. (NASDAQ: ISPC)
A vs ISPC Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, ISPC has a market cap of 2M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while ISPC trades at $0.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas ISPC's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to ISPC's ROE of -5.24%. Regarding short-term risk, A is less volatile compared to ISPC. This indicates lower risk in terms of short-term price fluctuations for A.Check ISPC's competition here
HTG Molecular Diagnostics, Inc. (NASDAQ: HTGM)
A vs HTGM Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, HTGM has a market cap of 1.1M. Regarding current trading prices, A is priced at $174.76 on the NYSE, while HTGM trades at $0.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas HTGM's P/E ratio is -0.03. In terms of profitability, A's ROE is +0.20%, compared to HTGM's ROE of -2.73%. Regarding short-term risk, A is more volatile compared to HTGM. This indicates higher risk in terms of short-term price fluctuations for A.Check HTGM's competition here
Biocept, Inc. (NASDAQ: BIOC)
A vs BIOC Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BIOC has a market cap of 450.8K. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BIOC trades at $0.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BIOC's P/E ratio is -0.01. In terms of profitability, A's ROE is +0.20%, compared to BIOC's ROE of -1.38%. Regarding short-term risk, A is less volatile compared to BIOC. This indicates lower risk in terms of short-term price fluctuations for A.Check BIOC's competition here
SeqLL Inc. (NASDAQ: SQLLW)
A vs SQLLW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, SQLLW has a market cap of 179.6K. Regarding current trading prices, A is priced at $174.76 on the NYSE, while SQLLW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas SQLLW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to SQLLW's ROE of -30.46%. Regarding short-term risk, A is less volatile compared to SQLLW. This indicates lower risk in terms of short-term price fluctuations for A.Check SQLLW's competition here
GeneDx Holdings Corp. (NASDAQ: WGSWW)
A vs WGSWW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, WGSWW has a market cap of 5.8K. Regarding current trading prices, A is priced at $174.76 on the NYSE, while WGSWW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas WGSWW's P/E ratio is -0.00. In terms of profitability, A's ROE is +0.20%, compared to WGSWW's ROE of -0.39%. Regarding short-term risk, A is more volatile compared to WGSWW. This indicates higher risk in terms of short-term price fluctuations for A.Check WGSWW's competition here
Ortho Clinical Diagnostics Holdings plc (NASDAQ: OCDX)
A vs OCDX Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, OCDX has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while OCDX trades at $17.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas OCDX's P/E ratio is -42.28. In terms of profitability, A's ROE is +0.20%, compared to OCDX's ROE of +0.18%. Regarding short-term risk, A is more volatile compared to OCDX. This indicates higher risk in terms of short-term price fluctuations for A.Check OCDX's competition here
PAREXEL Intl Corp. (NASDAQ: PRXL)
A vs PRXL Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, PRXL has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while PRXL trades at $88.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas PRXL's P/E ratio is 42.97. In terms of profitability, A's ROE is +0.20%, compared to PRXL's ROE of +0.17%. Regarding short-term risk, A is more volatile compared to PRXL. This indicates higher risk in terms of short-term price fluctuations for A.Check PRXL's competition here
ENDRA Life Sciences Inc. Warrants (NASDAQ: NDRAW)
A vs NDRAW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, NDRAW has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while NDRAW trades at $0.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas NDRAW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to NDRAW's ROE of -2.25%. Regarding short-term risk, A is less volatile compared to NDRAW. This indicates lower risk in terms of short-term price fluctuations for A.Check NDRAW's competition here
Danaher Corporation (NYSE: DHR-PA)
A vs DHR-PA Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, DHR-PA has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while DHR-PA trades at $1,841.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas DHR-PA's P/E ratio is 233.57. In terms of profitability, A's ROE is +0.20%, compared to DHR-PA's ROE of +0.08%. Regarding short-term risk, A is more volatile compared to DHR-PA. This indicates higher risk in terms of short-term price fluctuations for A.Check DHR-PA's competition here
Check-Cap Ltd (NASDAQ: CHEKZ)
A vs CHEKZ Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, CHEKZ has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while CHEKZ trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas CHEKZ's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to CHEKZ's ROE of +4.17%. Regarding short-term risk, A is less volatile compared to CHEKZ. This indicates lower risk in terms of short-term price fluctuations for A.Check CHEKZ's competition here
23andMe Holding Co. (NASDAQ: MEUSW)
A vs MEUSW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, MEUSW has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while MEUSW trades at $1.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas MEUSW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to MEUSW's ROE of -3.47%. Regarding short-term risk, A is less volatile compared to MEUSW. This indicates lower risk in terms of short-term price fluctuations for A.Check MEUSW's competition here
BioNano Genomics, Inc. WT EXP 082123 (NASDAQ: BNGOW)
A vs BNGOW Comparison November 2026
Agilent Technologies, Inc. (NYSE: A) plays a significant role within the Healthcare sector. Its performance on the NYSE reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, A stands at 49.3B. In comparison, BNGOW has a market cap of 0. Regarding current trading prices, A is priced at $174.76 on the NYSE, while BNGOW trades at $0.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
A currently has a P/E ratio of 30.08, whereas BNGOW's P/E ratio is N/A. In terms of profitability, A's ROE is +0.20%, compared to BNGOW's ROE of -0.79%. Regarding short-term risk, A is less volatile compared to BNGOW. This indicates lower risk in terms of short-term price fluctuations for A.Check BNGOW's competition here